Get the Stockscreener App
0.2027
15.06%
-0.0373
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Virpax Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:VRPX - Benzinga
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com Australia
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data - TipRanks
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
Virpax(R) Pharmaceuticals to Present at ThinkEquity Conference - ACCESS Newswire
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax reports positive study results for pain management drug - MSN
Breakthrough in Pain Relief: Virpax Pharmaceuticals Soars with US Army Collaboration - Bit Perfect Solutions
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Benzinga
Virpax reports positive study results for pain management drug By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur - TipRanks
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - StockTitan
Promising Nanotechnology Stocks To Follow TodayFebruary 11th - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 08th - MarketBeat
Promising Nanotechnology Stocks To Watch TodayFebruary 06th - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 05th - MarketBeat
Promising Nanotechnology Stocks To Watch Today – February 06th - Armenian Reporter
Virpax Pharmaceuticals Inc (VRPX) Stock: What the Analysts are Saying - The News Heater
Virpax Pharmaceuticals Appoints Charn Deol as Independent DirectorVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) announced on February 5, 2025, the appointment of Mr. Charn Deol as an independent director of the Company, effective immediately. Mr. D - Defense World
Virpax Pharmaceuticals appoints new independent director By Investing.com - Investing.com Australia
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals Appoints Charn Deol as Independent Director - TipRanks
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Board Member Jay Panis Resigns - TipRanks
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
VRPXVirpax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Clinical Trials Innovation: Virpax Leadership Takes Center Stage at Elite OCT Conference - StockTitan
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - The Manila Times
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals Announces $6 Mln Public Offering For Pain Relief Innovations - Nasdaq
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):